Alector, Inc.
No SEC Form 4 filings for $ALEC in the last 30 days.
See all $ALEC insider activity →Alector, Inc. (ALEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’
GSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
Alector, Inc. (ALEC) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. 8-K false 0001653087 0001653087 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,
Over the past 7 days, alphai's AI scored 1 news story mentioning ALEC (Alector, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ALEC coverage spans insider activity, corporate actions and earnings.
The filing updates runway and provides concrete IND timing targets for its lead ABC program, which can shift biotech risk pricing.
GSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
Termination of the GSK collaboration and associated debt repayment are credit and pipeline-risk negatives, but the cash outflow is capped by the disclosed payoff amount.
This is routine corporate governance disclosure with no new financial guidance or material transaction terms.
Large, multi-horizon EPC award should support revenue visibility over 10–36 months, but client/scope opacity limits near-term earnings precision.
alphai scores every news story that mentions ALEC with an AI model for sentiment and relevance, and aggregates insider trades from Alector, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alector, Inc. (ALEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’
6 min readGSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
4 min readAlector, Inc. (ALEC) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. 8-K false 0001653087 0001653087 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,
4 min readAlector, Inc. (ALEC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001653087 0001653087 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min readALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.
3 min readRosenthal Arnon (Chief Executive Officer) sold 87,216 shares of Alector, Inc. (ALEC) at $1.97 ($0.17M total) on 2026-06-02.
2 min readWong-Sarad Grace (Principal Accounting Officer) sold 3,475 shares of Alector, Inc. (ALEC) at $1.88 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min readWong-Sarad Grace (Principal Accounting Officer) sold 5,709 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.
2 min readBerkley Neil Lindsay (CFO & Chief Business Officer) sold 19,360 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.
2 min readAlector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.
4 min read
